Moffitt logo

Clinical Trials Search

Clinical Trial 19491

Cancer Type: Multiple
Interventions:BMS-936558 (Nivolumab); IRX-2; Nivolumab; cyclophosphamide; cytoxan (cyclophosphamide)

Study Type: Treatment
Phase of Study: Phase I
Investigators:

  • Solmaz Sahebjam

Call 813-745-6100
or 1-800-679-0775
Overview

Study Title

The IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity

Summary

Objective

Primary Objective: - To determine the safety profile of the combination of IRX-2 regimen with nivolumab. Secondary Objective(s): - To evaluate the objective clinical response rate of IRX-2 regimen combined with nivolumab using RECIST 1.1 and immune modified RECIST criteria . - To evaluate the progression-free survival of combination therapy at 6 and 12 months. Exploratory Objective(s): - To evaluate the biological effects of combination therapy determined by changes in the density of lymphocyte infiltration in the tumor and tumor microenvironment. - To evaluate the biological effects of combination therapy determined by changes in the T-cell receptor repertoire diversity. - To evaluate the biological effects of combination therapy determined by evaluation of peripheral blood mononuclear cells.

Inclusion Criteria

  • At least 18 years of age
  • Participants must have histologically or cytologically confirmed renal cell carcinoma,urothelial carcinoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck or melanoma.
  • Participants must have recurrent or metastatic disease that is not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
  • Must be willing and able to give informed consent and adhere to protocol therapy; written informed consent and any locally required authorization must be obtained from the participant prior to performing any protocol-related procedures, including screening evaluations
  • Prior exposure to PD-1/PD-L1 inhibitor monotherapy, or prior exposure to CTLA-4 inhibitor monotherapy is allowed.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Adequate normal organ and marrow function
  • Participants who are receiving therapeutic anti-coagulant therapy are eligible.
  • Palliative radiation therapy is allowed to non-target lesions at the discretion of the treating physician.
  • Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as outlined in RECIST version 1.1.
  • Life expectancy of greater than 3 months.
  • Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to treatment.
  • Body weight must be greater than 66 pounds.

  • Exclusion Criteria

  • Prior exposure to a combination of IRX-2 regimen, PD-1/PD-L1 inhibitors and CTLA-4 inhibitors are excluded. Prior exposure to PD-1/PD-L1 inhibitors is allowed.
  • Radiation therapy with a curable intent within 30 days of first dose of study treatment is excluded. However, radiation therapy with a palliative intent is allowed to treat after 14 days from the last dose of radiation.
  • Any medical contraindications or previous therapy that would preclude treatment with the IRX-2 Regimen, or nivolumab.
  • Any unresolved toxicity Grade 2 or greater from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.
  • Participants with irreversible toxicity not reasonably expected to be exacerbated by treatment with IRX-2, or nivolumab may be included only after consultation with the study physician.
  • Active or prior documented autoimmune or inflammatory disorders
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment. Some exceptions apply.
  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable.
  • History of allogenic organ transplantation.
  • Symptomatic cardiopulmonary disease, coronary artery disease, serious arrhythmia or chronic lung disease. Participants with these conditions who are stable with relatively minor symptoms and who are appropriate candidates for systemic treatments need not be excluded.
  • Myocardial infarction within the last 3 months.
  • Known infection with hepatitis B, hepatitis C, or HIV.
  • Signs or symptoms of systemic infection (use of antibiotics to treat superficial infection or contamination of tumor shall not, by itself, be considered evidence of infection).
  • Clinically significant gastritis or peptic ulcer disease
  • Stroke or other symptoms of cerebral vascular insufficiency within the last 3 months.
  • Allergy to ciprofloxacin (or other quinolones).
  • Previous diagnosis of invasive cancer from which the individual is not disease-free AND that has required treatment within the past 3 years, except for superficial skin, cervical cancer in-situ, or early stage prostate or bladder cancer (i.e. treatment with curative intent and long term disease-free expectations).
  • History of leptomeningeal carcinomatosis
  • Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
  • Female participants who are pregnant or breastfeeding or male or female participants of reproductive potential who are not willing to employ effective birth control from screening to 1 year after the last dose of study treatment.